... capital, and startup plans for public offerings are back in the spotlight. The largest funds and corporations have resumed significant venture investments, launching new funds and programs; governments in various countries are increasing support for innovation to keep pace in the global technology race. Preliminary data indicates that the first half of 2025 was the most successful in venture funding since 2021. In North America alone, investments during this period increased by approximately 87% ...

... with unprecedented capital-raising deals being struck and startup plans for going public returning to the agenda. Major corporations are resuming bold investments, launching new funds, while governments across various nations are ramping up support for innovation, keen to keep pace in the global technological race. Preliminary data indicates that the total venture financing volume in the first half of 2025 reached its highest level since early 2022. In the second quarter, global investments in startups ...

... record deals are being made for capital raising, and startups' plans to go public have returned to the agenda. Major corporations have resumed large-scale venture investments, and governments across various countries are increasing their support for innovation, eager not to lag in the global technology race. The first half of 2025 has become the most productive since 2021 in terms of venture investments, which reinforces optimism in the market. Venture deals span all regions—from Silicon Valley ...

... amounts of capital, and startup plans for IPOs are back in the spotlight. Major funds and corporations are resuming large-scale venture investments, launching new funds and initiatives; governments in various countries are increasing their support for innovation, striving not to fall behind in the global technology race. According to preliminary data, the first half of 2025 has become the most successful period for venture financing since 2021. In North America alone, investment volume during this ...

Genetiko is launching an additional share issue (SPO) at a price of 34 rubles per share. This strategic decision is aimed at raising capital to expand genetic research, enter international markets and develop innovative drugs for the treatment of orphan diseases. In this article, we will consider the goals of the SPO, possible prospects and key points that investors should consider. Find out how Genetiko plans to use the funds for further growth and strengthening ...